Leqvio (Inclisiran) Side Effects, Withdrawal, and Discontinuation: What Women Need to Know

What Leqvio Is and How It Works in Women's Bodies

Leqvio (inclisiran) belongs to a class that most women have never heard of: small interfering RNA (siRNA) therapeutics. It does not act like a statin. Instead, it silences a gene inside liver cells that codes for PCSK9, a protein that destroys LDL receptors on the surface of liver cells. Fewer PCSK9 molecules means more LDL receptors survive on the surface, and those receptors pull more LDL-C out of your bloodstream.

The practical consequence of this mechanism is a very long duration of action. A single subcutaneous injection produces meaningful LDL-C lowering for roughly six months, which is why the FDA-approved dosing schedule calls for a starter dose, a second dose at three months, and then one injection every six months thereafter.

Why This Mechanism Matters for Your Side-Effect Profile

Because inclisiran acts intracellularly in the liver and does not circulate in the bloodstream as a conventional small molecule, it produces very different side effects from statins. Muscle pain (myalgia) and the elevated liver enzymes seen with some statins are not a feature of inclisiran's side-effect profile in clinical trials. The drug's effects are almost entirely concentrated at the injection site and, to a lesser degree, in lipid and inflammatory biomarkers.

Sex-Specific Pharmacokinetics

The inclisiran prescribing information reports that sex does not require a dose adjustment. Population pharmacokinetic modeling from the ORION program showed that body weight had a modest effect on drug exposure, and since women on average have lower body weight and different fat distribution than men, their peak plasma concentrations may be slightly higher. The FDA label does not translate this into a clinical dose change, but the pharmacokinetic difference is real. Whether this marginally higher exposure produces any difference in efficacy or tolerability in women has not been studied in a sex-stratified analysis published to date. That is an evidence gap worth naming plainly.

The Most Common Side Effects of Leqvio in Clinical Trials

The most common side effect is an injection-site reaction. That is the clearest finding from the Phase 3 ORION program, and it deserves specificity.

Injection-Site Reactions: What the Data Show

In ORION-10, a 1,561-patient placebo-controlled trial published in the New England Journal of Medicine in 2020, injection-site adverse events occurred in 9.4% of inclisiran-treated patients compared with 0.5% of placebo recipients. These reactions included pain, erythema, and mild swelling at the injection site. Nearly all were rated mild or moderate in severity. None in the published ORION trials led to anaphylaxis. None required hospitalization.

In ORION-11, a separate 1,617-patient trial run simultaneously and published alongside ORION-10, the injection-site adverse event rate was 8.2% with inclisiran versus 0.9% with placebo.

The combined analysis of ORION-9, ORION-10, and ORION-11 (the ORION pooled dataset covering more than 3,600 patients) showed a consistent injection-site reaction rate of approximately 8-9% with no increase in rate or severity over time with repeated injections.

Upper Respiratory and Other Common Events

Beyond injection-site reactions, the ORION trials reported the following adverse events at a rate greater than 3% and numerically higher than placebo:

• Upper respiratory tract infections (approximately 7%)
• Urinary tract infections (approximately 4%)
• Arthralgia (approximately 5%)
• Nasopharyngitis (approximately 9%)
• Back pain (approximately 6%)
• Bronchitis (approximately 4%)

None of these reached statistical significance as drug-related in the pooled analysis. Rates were consistent with background rates for the age group studied. UTI rates are worth flagging for women because urinary tract infections are already more common in women and could be misattributed to the drug.

Laboratory Changes

Inclisiran produced no clinically meaningful increase in creatine kinase (the muscle enzyme elevated by statin-related myopathy), no increase in liver aminotransferases above three times the upper limit of normal in the pooled ORION data, and no consistent effect on blood glucose. This last point matters for women with PCOS, where statin use has been associated with a small increase in insulin resistance. Inclisiran does not appear to share that liability, though dedicated PCOS trials have not been run.

Rare and Serious Adverse Events: What Post-Market Data Show

The ORION trials were powered to detect lipid efficacy, not rare safety signals. Post-market surveillance through the FDA Adverse Event Reporting System (FAERS) provides a supplementary, though uncontrolled, picture.

Hypersensitivity and Allergic Reactions

Severe hypersensitivity to inclisiran has been reported rarely in post-market use. The drug contains cholesterol and PEG-lipid excipients that are structurally similar to those in some mRNA vaccine formulations. Women with known PEG allergies should discuss this with their clinician before their first injection. FAERS case reports include isolated cases of urticaria and angioedema, though causality cannot be confirmed from voluntary reports.

Hepatic Events

Serious hepatic events have not emerged as a defined signal in the ORION dataset. Clinically significant liver enzyme elevation (>3 times ULN) occurred in less than 1% of inclisiran recipients in the Phase 3 pool and was not significantly different from placebo. Post-market reports of hepatic events exist in FAERS but have not generated a regulatory safety communication from the FDA as of early 2025.

Cardiovascular Outcomes

ORION-4, a large ongoing cardiovascular outcomes trial enrolling more than 15,000 patients, is assessing whether inclisiran reduces major adverse cardiovascular events (MACE). Results are anticipated in the mid-2020s. Until ORION-4 reports, inclisiran has no completed cardiovascular outcomes trial. It is currently approved on the basis of LDL-C lowering as a surrogate endpoint, not demonstrated MACE reduction. Women considering Leqvio for secondary prevention should understand this distinction.

The WomanRx Discontinuation Framework for Inclisiran outlines three clinical scenarios clinicians at WomanRx use when a patient wants to stop Leqvio:

1. Planned pregnancy: Stop before conception given teratogenicity concerns; expect LDL-C to begin rising within 3-4 months of the last dose and return close to pre-treatment baseline by 9-12 months.
2. Intolerance (injection-site reactions): Dose can be delayed but not easily preemptively modified; consider alternative PCSK9 inhibitors (evolocumab, alirocumab) given subcutaneously but more frequently.
3. Financial or access disruption: LDL-C will rebound; bridge with maximally tolerated statin plus ezetimibe while access is re-established.

Does Leqvio Cause a Withdrawal Syndrome?

No. There is no pharmacological withdrawal syndrome when you stop inclisiran.

This is a fundamentally different situation from stopping corticosteroids, opioids, benzodiazepines, or even some antidepressants, which act on receptors in a way that creates physiological dependence. Inclisiran silences a hepatic gene. When the drug clears, the gene resumes normal expression. There is no receptor up-regulation, no rebound excitation, and no autonomic instability.

What Does Happen When You Stop

What you will experience after discontinuation is a gradual return of your LDL-C toward its pre-treatment level. The timeline follows the drug's mechanism. Because inclisiran produces lasting gene silencing through intracellular RNA interference, LDL-C remains suppressed for several months after the last injection. In the ORION-9 extension data, LDL-C began to rise approximately 3-4 months after a missed or final dose and returned to near-baseline levels by 9-12 months.

This LDL-C rebound is not a withdrawal symptom. It is simply the return of your underlying condition. If you have familial hypercholesterolemia (FH) or established cardiovascular disease, that rebound carries real risk, and you and your clinician should have a plan before stopping.

Patient-Reported Discontinuation Symptoms

Some patients report fatigue, muscle aches, or general malaise after stopping inclisiran and attribute these to the drug's discontinuation. There is no biological mechanism that explains these symptoms as inclisiran-specific, and the ORION trial data do not capture systematic discontinuation symptom reporting. These symptoms may reflect the underlying conditions that drove the prescription (e.g., cardiovascular disease, hypothyroidism, menopause-related fatigue) or coincidental illness. If you experience new symptoms after stopping any medication, report them to your clinician rather than self-attributing them to discontinuation.

Leqvio Side Effects Across Women's Life Stages

Reproductive-Age Women (18-40 Years)

Atherosclerotic cardiovascular disease (ASCVD) at a young age in women is often associated with familial hypercholesterolemia. Heterozygous FH affects approximately 1 in 250 people, and women with FH face an accelerated coronary risk that often goes unrecognized because risk calculators underestimate their 10-year risk at younger ages. Inclisiran is approved for adults with FH and high cardiovascular risk who need additional LDL-C lowering beyond statins. For a reproductive-age woman in this situation, the contraindication in pregnancy is the governing concern (see below).

Women with PCOS

PCOS is associated with dyslipidemia, specifically elevated triglycerides, low HDL-C, and elevated small, dense LDL particles. Whether inclisiran's 50% reduction in LDL-C is the right tool for PCOS-associated dyslipidemia depends on the individual's LDL-C level and cardiovascular risk category. Standard-of-care for PCOS-associated lipid abnormalities per ACOG Practice Bulletin on PCOS begins with lifestyle modification and, if indicated, statins. Inclisiran occupies a higher tier. For women with PCOS who also have FH or established ASCVD, it is a reasonable add-on if LDL-C targets are not met. The specific interaction between inclisiran and the insulin-resistance metabolic milieu of PCOS has not been studied in a dedicated trial.

Perimenopausal Women (Typically 40-55 Years)

The menopausal transition brings a well-documented shift in lipid profiles. LDL-C rises by an average of 10-14 mg/dL in the perimenopausal years, as shown in the Study of Women's Health Across the Nation (SWAN). HDL-C falls modestly. This is the life stage where many women first meet criteria for lipid-lowering therapy. Inclisiran would enter consideration only if statin plus ezetimibe therapy fails to reach LDL-C targets, or if statin intolerance is documented. The injection-site reaction profile is the same across age groups in the ORION data; no age-stratified worsening was reported.

Menopausal hormone therapy (MHT) effects on lipids are complex: oral estrogen lowers LDL-C but raises triglycerides, while transdermal estrogen is more lipid-neutral. A woman starting MHT during a course of inclisiran therapy should have her lipid panel re-checked at 3 months to see whether MHT's LDL-lowering effect changes the calculus for continuing the more expensive siRNA therapy.

Postmenopausal Women

Postmenopausal women carry the highest absolute ASCVD risk among women and are the most likely to be eligible for inclisiran in clinical practice. The ORION-10 and ORION-11 trials enrolled predominantly postmenopausal women with established ASCVD or FH. The efficacy and safety findings above apply most directly to this group. A 50% time-averaged LDL-C reduction on top of background statin therapy in a postmenopausal woman with prior myocardial infarction is a clinically meaningful intervention.

Pregnancy, Lactation, and Contraception: The Full Picture

Leqvio (inclisiran) is contraindicated in pregnancy. This is the single most important piece of safety information for any woman of reproductive potential considering this drug.

Animal Data and Human Pregnancy Category

Animal reproduction studies showed embryo-fetal toxicity at exposures below the maximum recommended human dose. The FDA prescribing label advises that inclisiran should be discontinued at least 17 months before a planned pregnancy. That window is long because the drug produces lasting RNA-silencing effects that outlast the detectable presence of the molecule itself.

No adequate human pregnancy data exist. There have been no prospective registry studies of inclisiran exposure in pregnancy as of early 2025. Given the drug's mechanism (hepatic gene silencing affecting lipid metabolism), animal findings of embryo-fetal harm are biologically plausible and cannot be dismissed.

Contraception Requirement

Women of reproductive potential should use effective contraception during inclisiran treatment and for 17 months after the last dose. The FDA label is explicit on this point. Hormonal contraceptives (combined oral contraceptive pills, the patch, the ring, the hormonal IUD, the implant, or the injectable) are all considered effective options. The copper IUD is also highly effective and avoids any theoretical interaction with hormonal methods.

Lactation Safety

It is unknown whether inclisiran or its metabolites are present in human breast milk. Animal lactation studies have not been published. Because cholesterol is essential for infant brain development and LDL-lowering in a breastfed infant is not desirable, the FDA label advises against breastfeeding during treatment and for 17 months after the last dose. This is a conservative but defensible position given the complete absence of human lactation data.

Trying to Conceive

If you are actively trying to conceive and are currently on Leqvio, the 17-month post-dose window means you should discuss stopping the drug with your cardiologist or lipid specialist well in advance. Your LDL-C will rise after stopping. For women with FH who are trying to conceive, the temporary rise in LDL-C during pregnancy is a known and managed risk; ACOG guidance on FH in pregnancy and specialist consultation with a maternal-fetal medicine physician experienced in lipid management is strongly recommended.

Who This Drug Is Right For and Who Should Avoid It

Likely Right For You If:

• You are postmenopausal with established ASCVD (prior MI, stroke, or peripheral artery disease) and your LDL-C remains above your target despite maximally tolerated statin plus ezetimibe
• You have heterozygous or homozygous familial hypercholesterolemia and need add-on LDL-C lowering
• You have documented statin intolerance and need a non-statin LDL-lowering option
• You find the twice-yearly injection schedule more manageable than daily oral medications

Likely Not Right For You If:

• You are pregnant, planning pregnancy within the next 17 months, or currently breastfeeding
• You have mild to moderate LDL-C elevation that can be managed with lifestyle plus a statin
• You have a known PEG allergy (discuss with your clinician before the first dose)
• You are a younger woman with PCOS whose dyslipidemia is primarily triglyceride or HDL-driven rather than LDL-driven

Monitoring and Managing Side Effects at Home

Injection-Site Reactions

Most injection-site reactions resolve within 24-48 hours without treatment. Applying a cold pack to the site before and immediately after injection reduces local discomfort. Rotating injection sites (upper arm, thigh, abdomen) between doses is recommended in the prescribing label. If you develop a reaction that spreads, increases in warmth after 48 hours, or is accompanied by fever, contact your clinician to rule out infection.

Tracking Your LDL-C

Leqvio's effect on LDL-C is maximal at around 30-60 days after each dose, then plateaus. Your clinician should check a fasting lipid panel approximately 3 months after your first dose and annually thereafter. If you miss a scheduled injection by more than three months, your LDL-C will have begun to rise. Missing a dose is not dangerous in the short term, but rescheduling promptly is important.

When to Call Your Clinician

Call your clinician promptly if you experience any of the following after a Leqvio injection:

• Hives, throat tightening, or difficulty breathing within 30 minutes of the injection
• Severe or spreading redness or swelling at the injection site that persists beyond 72 hours
• New or worsening muscle pain (to rule out other causes)
• Jaundice or marked fatigue (rare; warrants liver function testing)

The Evidence Gap: What We Still Do Not Know About Leqvio in Women

Women made up approximately 40-45% of the ORION-9, ORION-10, and ORION-11 trial populations, a proportion better than many older cardiovascular trials but still not sufficient for powered sex-stratified safety analyses. Published ORION sub-group analyses report sex as a modifier of efficacy in forest plots, with broadly consistent LDL-C reduction in women and men, but detailed sex-stratified adverse event tables have not been published in peer-reviewed journals.

Specific areas where women's data are absent or thin:

• Sex-stratified injection-site reaction severity and resolution time
• Inclisiran safety and efficacy in women with active PCOS
• Interaction between inclisiran and combined hormonal contraceptives
• Inclisiran pharmacokinetics in perimenopausal women experiencing rapid hormonal flux
• Long-term cardiovascular outcomes data in women (awaiting ORION-4)

"We still lack high-quality, sex-disaggregated safety data for most novel lipid-lowering agents, and inclisiran is no exception," as noted in a 2023 review of sex differences in PCSK9 inhibitor trials published in the Journal of the American Heart Association. When you make a shared decision with your clinician about inclisiran, you deserve to know that some of the reassurance we can offer is extrapolated from a population where women were a minority.